Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms BCD-248 |
Target |
Action modulators, stimulants |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory Multiple Myeloma | Phase 2 | Russia | 26 Dec 2024 | |
| Relapse multiple myeloma | Phase 2 | Russia | 26 Dec 2024 |






